Olaparib

Olaparib is a small-molecule poly(ADP-ribose) polymerase inhibitor used in oncology drug development. It inhibits PARP-mediated DNA-repair activity and promotes retention of PARP on damaged DNA, creating replication-associated stress. These complementary actions are particularly relevant in tumor models with deficient homologous-recombination repair, including selected BRCA-associated settings.

The compound’s pharmaceutical performance also depends on how the drug is presented in a solid oral formulation. Its limited aqueous solubility makes dissolution and drug dispersion important development subjects. The selected material is the unformulated drug substance, allowing evaluation of solid-state behavior, excipient compatibility and release from tablets. Biological research uses the same defined molecule to investigate DNA-repair dependence and treatment combinations.

Typical Applications

• Oral oncology formulation development: Used as the active ingredient in tablet-development work involving drug dispersion, dissolution, excipient compatibility and stability of olaparib-containing oral dosage forms.
• DNA-repair and synthetic-lethality studies: Used in cellular and tumor models to examine PARP inhibition, PARP trapping and sensitivity associated with homologous-recombination repair defects.
• Combination-treatment research: Used alongside DNA-damaging agents or other pathway inhibitors in laboratory studies that examine whether complementary mechanisms alter tumor-cell response or resistance.

Specifications

Specifications describe the standard grade. Tolerance, test method and documentation package are confirmed per order.